Novel Drug Development in Breast Cancer OncLive Recently, the phase III BOLERO-3 trial examined the addition of everolimus to the combination of trastuzumab and vinorelbine in women with HER2-positive metastatic breast cancer. The median progression-free survival with the addition of everolimus was ... |
